Sickle Cell Anemia Patients in Use of Hydroxyurea: Association between Polymorphisms in Genes Encoding Metabolizing Drug Enzymes and Laboratory Parameters

Table 2

Genotype frequencies of MPO −463G>A, NQO1 609C>T, CYP2E1 −1293G>C/−1053C>T, GSTT1, and GSTM1 polymorphisms using the dominant genetic model in SCA patients treated (SCA-HU⁺) and untreated (SCA-HU⁻) with HU.

Genotypes	SCA-HU^+ patients; N (%)	SCA-HU^− patients; N (%)	OR; (95% CI)	value
MPO −463G>A	(100%)	(100%)
GG	10 (28.57%)	34 (51.52%)	2.66	0.045
GA + AA	25 (71.43%)	32 (48.48%)	(1.10–6.39)
NQO1 609C>T	(100%)	(100%)
CC	24 (68.57%)	41 (61.19%)	0.72	0.604
CT + TT	11 (31.43%)	26 (38.81%)	(0.30–1.72)
CYP2E1 −1293G>C/−1053C>T	(100%)	(100%)
c1c1	26 (74.29%)	63 (94.03%)	5.45	0.009
c1c2 + c2c2	9 (25.71%)	4 (5.97%)	(1.54–19.28)
GSTT1	(100%)	(100%)
GSTT1+	26 (74.29%)	49 (73.13%)	0.94	0.911
GSTT1−	9 (25.71%)	18 (26.87%)	(0.37–2.39)
GSTM1	(100%)	(100%)
GSTM1+	21 (60%)	45 (67.16%)	1.36	0.616
GSTM1−	14 (40%)	22 (32.84%)	(0.58–3.18)

SCA-HU⁺: SCA patient treated with HU; SCA-HU⁻: SCA patient untreated with HU; MPO: myeloperoxidase; CYP2E1: cytochrome P450 2E1; GSTT1/GSTM1: glutathione S-transferase T1/M1; NQO1: NADP(H) quinone oxidoreductase; N: number; corrected Yates, exact Fisher test; OR: odds ratio; 95% CI: 95% confidence interval.